Insider Transactions in Q1 2023 at Biovie Inc. (BIVI)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2023
|
Richard J Berman Director |
SELL
Open market or private sale
|
Direct |
7,613
-9.53%
|
$60,904
$8.52 P/Share
|
|
Mar 27
2023
|
Richard J Berman Director |
SELL
Open market or private sale
|
Direct |
3,371
-7.46%
|
$26,968
$8.52 P/Share
|
|
Feb 16
2023
|
Cuong V Do President & CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
9,906
-1.62%
|
$49,530
$5.82 P/Share
|
|
Feb 16
2023
|
Joanne Wendy Kim Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,952
-5.78%
|
$24,760
$5.82 P/Share
|
|
Feb 16
2023
|
Joseph M Palumbo Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,952
-6.46%
|
$24,760
$5.82 P/Share
|
|
Feb 16
2023
|
Clarence N. Ahlem EVP Neuroscience Product Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,476
-6.25%
|
$14,856
$6.12 P/Share
|
|
Feb 16
2023
|
Penelope Markham EVP Liver Cirrhosis R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
2,476
-4.92%
|
$14,856
$6.12 P/Share
|
|
Feb 16
2023
|
Christopher Reading EVP Neuroscience R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
2,476
-6.25%
|
$14,856
$6.12 P/Share
|